Literature DB >> 34110601

Postoperatively determined high-risk histopathologic features in papillary thyroid carcinoma initially eligible for thyroid lobectomy: a game changer.

Sohail Bakkar1, Khaled Al-Omar2, Gianluca Donatini3, Qusai Aljarrah4, Theodosios S Papavramidis5, Gabriele Materazzi6, Paolo Miccoli6.   

Abstract

PURPOSE: Recent clinical practice guidelines consider thyroid lobectomy a viable alternative for low-risk papillary thyroid carcinoma PTC measuring 1-4 cm in size. We aimed to assess the likelihood of finding postoperatively determined high-risk histopathologic features that would lead to the recommendation of completion thyroidectomy.
METHODS: A retrospective review of patients who underwent total thyroidectomy for PTC measuring 1-4 cm in size between Jan 2012 and Jan 2018 was conducted. Patients with pre-operative high-risk characteristics were excluded: history of radiation exposure, positive family history, clinically suspicious cervical lymphadenopathy, and gross extrathyroidal extension (ETE). A hypothetical group of 245 patients remained eligible for lobectomy. The pathology specimens from the cancer-containing lobes were evaluated for high-risk features: aggressive histology, capsular and/or vascular invasion, microscopic ETE, and multifocality. A subgroup analysis was performed with 2 cm being the cut-off size.
RESULTS: The average age was 39 years with 73% being females. Mean cancer size was 16 mm. Evaluation of the cancer-containing lobe for high-risk features revealed: aggressive histology (33%), ETE (12%), capsular invasion (33%), vascular invasion (17%), and ipsilateral multifocality (30%). The cumulative risk of having ≥1 high-risk feature mandating completion thyroidectomy was 59%. The risk was considerably higher for lesions ≤2 cm compared to larger lesions (64% vs.48%; p = 0.049; RR = 1.3).
CONCLUSIONS: A considerable proportion of patients initially eligible for lobectomy have high-risk features that only become evident at pathology. Therefore, a comprehensive approach is advocated to determine the extent of surgery for PTC incorporating patient preferences regarding risks and benefits.

Entities:  

Keywords:  Extent of surgery; Low-risk; Papillary thyroid carcinoma; Thyroid lobectomy; Total thyroidectomy

Year:  2021        PMID: 34110601     DOI: 10.1007/s12020-021-02788-w

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  12 in total

Review 1.  Surgical management of papillary thyroid carcinoma: an overview.

Authors:  Paolo Miccoli; Sohail Bakkar
Journal:  Updates Surg       Date:  2017-04-12

2.  [Experiences with Thrombotison ointment in phlebitis, inflammations of the soft parts and leg ulcer].

Authors:  I Colombo
Journal:  Munch Med Wochenschr       Date:  1970-01-09

Review 3.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

4.  Surgical Management of Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma. Experience in 25 Patients.

Authors:  Claudio Spinelli; Silvia Strambi; Sohail Bakkar; Andrea Nosiglia; GianMarco Elia; Alessia Bertocchini; Chiara Calani; Matteo Leoni; Riccardo Morganti; Gabriele Materazzi
Journal:  World J Surg       Date:  2020-01       Impact factor: 3.352

5.  Impact of extent of surgery on survival for papillary thyroid cancer patients younger than 45 years.

Authors:  Mohamed Abdelgadir Adam; John Pura; Paolo Goffredo; Michaela A Dinan; Terry Hyslop; Shelby D Reed; Randall P Scheri; Sanziana A Roman; Julie A Sosa
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

Review 6.  Energy-based devices in thyroid surgery-an overview.

Authors:  Sohail Bakkar; Theodosios S Papavramidis; Qusai Aljarrah; Gabriele Materazzi; Paolo Miccoli
Journal:  Gland Surg       Date:  2020-01

Review 7.  Thyroid nodules and cancer management guidelines: comparisons and controversies.

Authors:  Fadi Nabhan; Matthew D Ringel
Journal:  Endocr Relat Cancer       Date:  2016-12-13       Impact factor: 5.678

8.  BRAFV600E mutation: a potential predictor of more than a Sistrunk's procedure in patients with thyroglossal duct cyst carcinoma and a normal thyroid gland.

Authors:  Sohail Bakkar; Elisabetta Macerola; Qusai Aljarrah; Agnese Proietti; Gabriele Materazzi; Fulvio Basolo; Paolo Miccoli
Journal:  Updates Surg       Date:  2019-10-04

9.  Thyroid cancer mortality and incidence: a global overview.

Authors:  Carlo La Vecchia; Matteo Malvezzi; Cristina Bosetti; Werner Garavello; Paola Bertuccio; Fabio Levi; Eva Negri
Journal:  Int J Cancer       Date:  2014-10-13       Impact factor: 7.396

10.  Impact of COVID-19 on thyroid cancer surgery and adjunct therapy.

Authors:  Sohail Bakkar; Khaled Al-Omar; Qusai Aljarrah; Moh'd Al-Dabbas; Nesrin Al-Dabbas; Samara Samara; Paolo Miccoli
Journal:  Updates Surg       Date:  2020-06-14
View more
  1 in total

Review 1.  [Hemithyroidectomy or total thyroidectomy for low-risk papillary thyroid cancer? : Surgical criteria for primary and secondary choice of treatment in an interdisciplinary treatment concept].

Authors:  H Dralle; F Weber; A Machens; T Brandenburg; K W Schmid; D Führer-Sakel
Journal:  Chirurgie (Heidelb)       Date:  2022-09-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.